Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 May 2017 Status changed from active, no longer recruiting to completed.
- 22 Jul 2014 Planned End Date changed from 1 Jun 2013 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 07 Feb 2013 New source identified and integrated (Mayo Clinic; 10-006476).